Cancer treatments that genetically modify patients blood cells to target the disease have shown amazing results in clinical trials Now drug companies and biotechs must overcome big hurdles to get them into hospitals including their potential cost In two separate clinical trialssponsored by Novartis AG of Switzerland and Seattlebased biotech Juno Therapeutics Incalmost  of patients saw their leukemia disappear after being given experimental socalled CAR Tcell therapies The results were published in December and
  